Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Sell
50
PRCT Quote, Financials, Valuation and Earnings
Last price:
$55.60
Seasonality move
:
14.56%
Day range:
$53.03 - $56.29
52-week range:
$47.04 - $103.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.86x
P/B ratio:
7.83x
Volume:
931.5K
Avg. volume:
1.2M
1-year change:
-9.91%
Market cap:
$3B
Revenue:
$224.5M
EPS (TTM):
-$1.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
$82.1M | -$0.36 | 42.41% | -20.29% | $76.88 |
|
BSX
Boston Scientific
|
$4.9B | $0.70 | 18.78% | 229.2% | $116.12 |
|
CATX
Perspective Therapeutics
|
$123.9K | -$0.35 | -- | -35.77% | $14.3929 |
|
RXST
RxSight
|
$40.8M | -$0.03 | 34.7% | -73.88% | $24.36 |
|
VNRX
VolitionRX
|
$1.3M | -$0.04 | 197.5% | -46.88% | $2.92 |
|
XTNT
Xtant Medical Holdings
|
$31.1M | -$0.01 | 9.96% | -33.33% | $1.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
$55.62 | $76.88 | $3B | -- | $0.00 | 0% | 11.86x |
|
BSX
Boston Scientific
|
$104.93 | $116.12 | $155.2B | 76.59x | $0.00 | 0% | 8.90x |
|
CATX
Perspective Therapeutics
|
$2.5600 | $14.3929 | $189.6M | -- | $0.00 | 0% | 16.57x |
|
RXST
RxSight
|
$15.85 | $24.36 | $641.8M | -- | $0.00 | 0% | 4.40x |
|
VNRX
VolitionRX
|
$0.48 | $2.92 | $46.7M | -- | $0.00 | 0% | 33.32x |
|
XTNT
Xtant Medical Holdings
|
$0.47 | $1.75 | $65.6M | -- | $0.00 | 0% | 0.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
12.09% | 2.173 | 1.68% | 7.60x |
|
BSX
Boston Scientific
|
33.49% | 1.029 | 7.48% | 0.68x |
|
CATX
Perspective Therapeutics
|
-- | -1.032 | -- | -- |
|
RXST
RxSight
|
-- | 2.476 | -- | 10.33x |
|
VNRX
VolitionRX
|
-28.76% | 1.111 | 8.83% | 0.19x |
|
XTNT
Xtant Medical Holdings
|
44.29% | -0.806 | 55.45% | 0.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
$44.2M | -$27.4M | -24.95% | -29.12% | -34.5% | -$33.6M |
|
BSX
Boston Scientific
|
$3.2B | $937M | 6.35% | 9.57% | 19.02% | $277M |
|
CATX
Perspective Therapeutics
|
-- | -$20.9M | -- | -- | -- | -$41.2M |
|
RXST
RxSight
|
$28.8M | -$8.6M | -11.86% | -11.86% | -14.72% | -$5.1M |
|
VNRX
VolitionRX
|
-- | -$5.8M | -- | -- | -1217.88% | -$5.5M |
|
XTNT
Xtant Medical Holdings
|
$16M | -$1.9M | -21.41% | -35.34% | -6.38% | -$7K |
PROCEPT BioRobotics vs. Competitors
-
Which has Higher Returns PRCT or BSX?
Boston Scientific has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of 14.45%. PROCEPT BioRobotics's return on equity of -29.12% beat Boston Scientific's return on equity of 9.57%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M BSXBoston Scientific68.84% $0.45 $33.6B -
What do Analysts Say About PRCT or BSX?
PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 38.22%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 10.67%. Given that PROCEPT BioRobotics has higher upside potential than Boston Scientific, analysts believe PROCEPT BioRobotics is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 BSXBoston Scientific23 4 0 -
Is PRCT or BSX More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.
-
Which is a Better Dividend Stock PRCT or BSX?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or BSX?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are smaller than Boston Scientific quarterly revenues of $4.7B. PROCEPT BioRobotics's net income of -$24.7M is lower than Boston Scientific's net income of $674M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 76.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.86x versus 8.90x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.86x -- $69.2M -$24.7M BSXBoston Scientific8.90x 76.59x $4.7B $674M
-
Which has Higher Returns PRCT or CATX?
Perspective Therapeutics has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of --. PROCEPT BioRobotics's return on equity of -29.12% beat Perspective Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M CATXPerspective Therapeutics-- -$0.61 -- -
What do Analysts Say About PRCT or CATX?
PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 38.22%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 462.22%. Given that Perspective Therapeutics has higher upside potential than PROCEPT BioRobotics, analysts believe Perspective Therapeutics is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 CATXPerspective Therapeutics10 1 0 -
Is PRCT or CATX More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.
-
Which is a Better Dividend Stock PRCT or CATX?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or CATX?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Perspective Therapeutics quarterly revenues of --. PROCEPT BioRobotics's net income of -$24.7M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.86x versus 16.57x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.86x -- $69.2M -$24.7M CATXPerspective Therapeutics16.57x -- -- -$40.2M
-
Which has Higher Returns PRCT or RXST?
RxSight has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -14.77%. PROCEPT BioRobotics's return on equity of -29.12% beat RxSight's return on equity of -11.86%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M RXSTRxSight71.59% -$0.15 $281.2M -
What do Analysts Say About PRCT or RXST?
PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 38.22%. On the other hand RxSight has an analysts' consensus of $24.36 which suggests that it could grow by 53.71%. Given that RxSight has higher upside potential than PROCEPT BioRobotics, analysts believe RxSight is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 RXSTRxSight3 4 0 -
Is PRCT or RXST More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRCT or RXST?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or RXST?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than RxSight quarterly revenues of $40.2M. PROCEPT BioRobotics's net income of -$24.7M is lower than RxSight's net income of -$5.9M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.86x versus 4.40x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.86x -- $69.2M -$24.7M RXSTRxSight4.40x -- $40.2M -$5.9M
-
Which has Higher Returns PRCT or VNRX?
VolitionRX has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -1226.82%. PROCEPT BioRobotics's return on equity of -29.12% beat VolitionRX's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M VNRXVolitionRX-- -$0.07 -$17.8M -
What do Analysts Say About PRCT or VNRX?
PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 38.22%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 515.58%. Given that VolitionRX has higher upside potential than PROCEPT BioRobotics, analysts believe VolitionRX is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 VNRXVolitionRX2 1 0 -
Is PRCT or VNRX More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.
-
Which is a Better Dividend Stock PRCT or VNRX?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or VNRX?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than VolitionRX quarterly revenues of $474.5K. PROCEPT BioRobotics's net income of -$24.7M is lower than VolitionRX's net income of -$5.8M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.86x versus 33.32x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.86x -- $69.2M -$24.7M VNRXVolitionRX33.32x -- $474.5K -$5.8M
-
Which has Higher Returns PRCT or XTNT?
Xtant Medical Holdings has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -10.04%. PROCEPT BioRobotics's return on equity of -29.12% beat Xtant Medical Holdings's return on equity of -35.34%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M XTNTXtant Medical Holdings50.85% -$0.02 $77.1M -
What do Analysts Say About PRCT or XTNT?
PROCEPT BioRobotics has a consensus price target of $76.88, signalling upside risk potential of 38.22%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 270.76%. Given that Xtant Medical Holdings has higher upside potential than PROCEPT BioRobotics, analysts believe Xtant Medical Holdings is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 XTNTXtant Medical Holdings2 0 0 -
Is PRCT or XTNT More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.
-
Which is a Better Dividend Stock PRCT or XTNT?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or XTNT?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. PROCEPT BioRobotics's net income of -$24.7M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.86x versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.86x -- $69.2M -$24.7M XTNTXtant Medical Holdings0.54x -- $31.5M -$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Is Adobe Stock a Bargain With AI Tools Driving Growth?
The share price of American computer software company Adobe (NASDAQ:ADBE)…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
